ap-sa02
·Code: AP-SA02
ap-sa02: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | Phase 1/Phase 2 |
FDA Decisions
FDA_MeetingFDA granted Qualified Infectious Disease Product (QIDP) designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.(ARMP)
Frequently asked questions
Who is developing ap-sa02?
ap-sa02 is being developed by Armata Pharmaceuticals, Inc..
What is ap-sa02's latest FDA decision?
The most recent tracked FDA decision for ap-sa02 is FDA_Meeting for FDA granted Qualified Infectious Disease Product (QIDP) designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA., dated February 23, 2026.
Get deeper analysis on ap-sa02
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis